Gracell Biotechnologies Stock Current Asset
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
Gracell |
Gracell Biotechnologies Company Current Asset Analysis
Gracell Biotechnologies' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Gracell Biotechnologies has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Gracell Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.Gracell Biotechnologies is currently under evaluation in current asset category among its peers.
Gracell Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Shares Owned By Insiders | 16.39 % | |||
| Shares Owned By Institutions | 63.11 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| Gross Profit | 366 K | |||
| EBITDA | (509.64 M) | |||
| Net Income | (496.98 M) | |||
| Cash And Equivalents | 1.71 B | |||
| Cash Per Share | 25.28 X | |||
| Total Debt | 182.98 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 8.01 X | |||
| Book Value Per Share | 16.90 X | |||
| Cash Flow From Operations | (482.65 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (0.97) X | |||
| Target Price | 10.58 | |||
| Number Of Employees | 314 | |||
| Beta | -0.34 | |||
| Market Capitalization | 989.87 M | |||
| Total Asset | 1.66 B | |||
| Retained Earnings | (1.63 B) | |||
| Working Capital | 1.28 B | |||
| Z Score | 1.78 | |||
| Net Asset | 1.66 B |
About Gracell Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gracell Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |